Insights+: Key Deals of JP Morgan Healthcare Conference 2021
NeuClone Reports Dosing of NeuLara (proposed biosimilar, ustekinumab) in P-I Trial
NeuClone to Initiate P-I Clinical Study of Stelara (ustekinumab, biosimilar) in Australia
Shots:
- Australian Therapeutic Goods Administration (TGA) Clinical Trial Notification (CTN) scheme is responsible for conducting the NeuLara P-I trial and is being conducted across 200 healthy volunteers assessing PK and safety of US- and EU-sourced Stelara
- NeuClone’s NeuLara is the second biosimilar in pipeline to enter in clinical development and is developed in partnership with Serum Institute of India
- NeuLara is a mAb targeting interleukin-12 and -23 developed to treat patients with plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis
Click here to read full press release/ article | Ref: NeuClone | Image: Twitter
